-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on ArriVent BioPharma, Maintains $42 Price Target

Benzinga·08/13/2026 10:14:12
Listen to the news
BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $42 price target.